Reviva Pharmaceuticals (NASDAQ:RVPH) Shares Down 13.5% – Here’s What Happened

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares traded down 13.5% on Wednesday . The stock traded as low as $0.4001 and last traded at $0.45. 18,491 shares traded hands during trading, a decline of 96% from the average daily volume of 413,993 shares. The stock had previously closed at $0.52.

Wall Street Analysts Forecast Growth

Several brokerages have commented on RVPH. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Price Performance

The stock’s 50 day moving average is $0.58 and its two-hundred day moving average is $1.99. The stock has a market capitalization of $5.62 million, a PE ratio of -0.11 and a beta of 0.53.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, equities analysts predict that Reviva Pharmaceuticals Holdings, Inc. will post -2.96 earnings per share for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RVPH. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. Geode Capital Management LLC raised its stake in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares in the last quarter. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals in the second quarter valued at $31,000. Armistice Capital LLC acquired a new position in Reviva Pharmaceuticals in the second quarter valued at $1,026,000. Finally, Lido Advisors LLC acquired a new position in Reviva Pharmaceuticals in the third quarter valued at $37,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.